MedPath

A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutatio

Phase 1
Conditions
on-Small Cell Lung Cancer
Registration Number
JPRN-UMIN000006273
Lead Sponsor
ational Hospital Organization Kyushu Medical Center Department of Respiratory Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
11
Inclusion Criteria

Not provided

Exclusion Criteria

1)Serious infections 2)Serious clinical problems 3)Interstitial pneumonia/lung fibrosis on chest CT 4)Active concomitant malignancy 5)Symptomatic brain metastasis 6)Massive pericardial, pleural effusion, ascites 7)Previous drug allergy 8)Those judged to be not suitable by the attending physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Maximum tolerated dose (MTD) of pemetrexed and gefitinib
Secondary Outcome Measures
NameTimeMethod
Anti tumor efficacy
© Copyright 2025. All Rights Reserved by MedPath